爱必信(上海)生物科技有限公司
欢迎联系我们! 服务热线: 021-38015121
 
 
产品展厅
VE-822, 1232416-25-9
  • 品牌:爱必信(absin)
  • 产地:中国
  • 货号:abs813881
  • cas:1232416-25-9
  • 价格: ¥1181/瓶
  • 发布日期: 2022-04-07
  • 更新日期: 2025-09-18
产品详请
产地 中国
品牌 爱必信(absin)
货号 abs813881
用途 见爱必信官网
英文名称 见爱必信官网
包装规格 10mg,10mg,10mg,10mg,50mg,50mg,50mg,50mg,5mg,5mg,5mg,5mg,25mg,25mg,25mg,25mg
纯度 >98%%
CAS编号 1232416-25-9
别名 VE 822
是否进口

公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!

 

抑制剂描述:

产品名称:VE-822

产品别名:见爱必信官网

英文别名:VE-822

靶点:ATM/ATR

CAS:1232416-25-9

纯度:>98%

外观:见爱必信官网

保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

描述:

VE-822是选择性ATR抑制剂,Ki< 0.2 nM,ATR选择性比高相关性的PI3K关联酶ATM/DNA-PK高了170倍。作为对XRT和gemcitabine的响应,VE-822(80 nM)减弱ATR信号传导途径,并降低肿瘤细胞存活率。在正常细胞中,VE-822(80 nM)减弱ATR信号通路强度,但并没有增强辐射和gemcitabine杀伤正常细胞的能力。与XRT中的MiaPaCa-2和PSN-1细胞相比,VE-822(80 nM)增加XRT引起的残余γH2AX和53BP1灶。

溶解性:DMSO :34 mg/mL (73.3 mM)

体外研究:

VE-822 (80 nM) attenuates ATR signaling pathway and reduces survival in tumor cells in response to XRT and gemcitabine. VE-822 (80 nM) attenuates ATR signaling in normal cells without enhancing radiation and gemcitabine killing in normal cells. VE-822 (80 nM) increases XRT-induced residual γH2AX and 53BP1 foci compared with XRT in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) pre-treatment decreases Rad51 foci after XRT in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) alone increases the G1-phase-fraction in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) abrogates XRT enriched G2/M-phase-fraction in MiaPaCa-2 and PSN-1 cells. VE-822 has little effect alone, while VE-822 (80 nM) combined with XRT and/or gemcitabine enhances early and late apoptosis in PSN-1 cells that is strongest in the triple combination. VE-822 increases tumor response to DNA damaging agents associated with blockade of pChk1 Ser345.

体内研究:VE-822 (60 mg/kg) inhibits phospho-Ser-345-Chk1 in mice bearing PSN-1 tumors after DNA-damaging agents. VE-822 (60 mg/kg) combined with XTR doubles the time for tumors to grow to 600 mm3 of XRT alone in mice bearing both PSN-1 and MiaPaCa-2 tumors. VE-822 (60 mg/kg) added to the combination of gemcitabine and XRT substantially prolongs the tumor growth delay compared with the Gem+XRT1 group n mice bearing both PSN-1 tumors. VE-822 (60 mg/kg) combined with XRT1 increases uptake in tumors by 44% compared with XRT1, suggesting that addition of VE-822 increased γH2AX phosphorylation and persistence of DNA damage caused by XRT.

产品信息订购:

  产品货号   产品名称   规格 价格 大包装及货期
  abs813881   VE-822   10mg   1181.00   立即咨询
  abs813881   VE-822   50mg   4030.00   立即咨询
  abs813881   VE-822   5mg   822.00   立即咨询
  abs813881   VE-822   25mg   2426.00   立即咨询

产品更多信息请进入爱必信网站咨询

联系方式
手机:18438616290